Press Release

Aquestive – $74 Million IPO

September 12, 2018

New York – September 12, 2018 – Cooley advised the underwriters on Aquestive Therapeutics' $73.9 million initial public offering of 4,925,727 shares of common stock, which includes the partial exercise of the underwriters’ option to purchase additional shares. Partners Daniel Goldberg, Ryan Sansom and Div Gupta led the Cooley team advising the underwriters.

BMO Capital Markets and RBC Capital Markets acted as the joint book-running managers for the offering. Wedbush PacGrow and JMP Securities acted as co-lead managers for the offering.

Aquestive Therapeutics, which now trades on the Nasdaq Global Market as “AQST,” is a specialty pharmacy company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. 

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.


This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.